Clinical trial · Observational
Meta-analysis of Efficacy of Topotecan
Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix
NCT01160185CI-TRIAL-00003656completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Intraepithelial Neoplasia | Cervical Intraepithelial Neoplasia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| paclitaxel | Drug | Paclitaxel | ALIAS |
| topotecan | Drug | Topotecan | ALIAS |
Design
Arms and outcomes
Arms (3)
- label
- cisplatin
- interventionNames
- Drug: cisplatin
- label
- cisplatin + topotecan
- interventionNames
- Drug: cisplatin
- Drug: topotecan
- label
- cisplatin + paclitaxel
- interventionNames
- Drug: paclitaxel
- Drug: cisplatin
Primary outcomes (1)
- measure
- Survival
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Randomised Clinical Trials or systematic reviews or meta-analyses * Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.